Company: MDCXW
Filing Date: 2025-06-13
Form Type: PRE 14A
Source: 0001062993-25-011673
Chunk: 96

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-13
Form: PRE 14A
Chunk 96
---
.

4.3.External Audit

(i)recommend the Auditor's nomination to the Board to be put forward before the shareholders for appointment and, as necessary, the removal of any Auditor in office from time to time;

<div align='center'>SC C-3</div>

(ii)ensure the Auditor reports directly to the Committee on a regular basis;

(iii)review the independence of the Auditor, including receiving a written report from the Auditor respecting its independence and consideration of applicable auditor independence standards and receiving from the Auditor a formal written statement delineating all relationships between the Auditor and the Company, actively engaging in a dialogue with the Auditor with respect to any disclosed relationships or services that may impact the objectivity and independence of the Auditor and taking appropriate action to oversee the independence of the outside Auditor;

(iv)recommend to the Board the compensation of the Auditor, and otherwise set the terms of the Auditor's engagement (including reviewing and negotiating the Auditor's engagement letter);

(v)review the audit plan of the external auditors prior to the commencement of the audit;

(vi)establish and maintain a direct line of communication with the Company's Auditor and, if applicable, the Company's internal auditors;

(vii)meet in camera with only the Auditor (if present), with only management of the Company (if present), and with only the Members at every Committee meeting;

(viii)review the performance of the external auditors who are accountable to the Committee and the Board as representatives of the shareholders, including the lead partner of the Auditor's team;

(ix)oversee the work of the Auditor with respect to preparing and issuing an audit report or performing other audit, review or attest services for the Company, including the resolution of issues between management of the Company and the Auditor regarding financial disclosure;

(x)review the results of the external audit and the report thereon including, without limitation, a discussion with the Auditor as to the quality of accounting principles used and any alternative treatments of financial information that have been discussed with management of the Company and the ramifications of their use, as well as any other material changes. Review a report describing all material written communication between management of the Company and the Auditor such as management letters and schedule of unadjusted differences;

(xi)discuss with the Auditor its perception of the Company's financial and accounting personnel, records and systems, the cooperation which the Auditor received during the course of their review and availability of records, data and other requested information and any recommendations with respect thereto;

(xii)review the reasons for any proposed change in the Auditor